Clinical Implication of Integrated PET-CT in the Patients With Pancreatic Cancer
N/A
18 Years
75 Years
18 Years
75 Years
Open (Enrolling)
Both
Pancreatic Cancer
Both
Pancreatic Cancer
Trial Information
Clinical Implication of Integrated PET-CT in the Patients With Pancreatic Cancer
Compared to dynamic phase pancreatic CT, integrated PET-CT will be evaluated for
sensitivity, specificity and accuracy of diagnosing and staging pancreatic cancer while the
gold standard for pancratic cancer is operative specimen. If the operation can't be
performed, EUS-FNA of the pancreatic mass or lymph node and additional imaging modality will
be preferred to laparotomy.
Inclusion Criteria:
- Pancreatic mass suspicious of pancreatic cancer
- No comorbidity, expected life expectancy less than 6 months
- Consent this study in letter
Exclusion Criteria:
- Refuse diagnostic and staging work-up
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
Staging of pancreatic cancer
Outcome Time Frame:
6 months after study start
Safety Issue:
No
Authority:
Korea: Food and Drug Administration
Study ID:
2008-0623
NCT ID:
NCT00885248
Start Date:
January 2009
Completion Date:
December 2009
Related Keywords:
- Pancreatic Cancer
- pancreatic cancer
- integrated PET-CT
- Pancreatic Neoplasms
Name | Location |
|---|
